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1. INTRODUCTION
In late 2010, internationally respected Canadian 
authorities in ovarian cancer convened in Toronto, 
Ontario, to discuss the relevance of progression-free 
survival (pfs) as an endpoint in treatment and also the 
importance of pfs and its impact on the development 
of clinical trials. This pan-Canadian workshop was 
led by Dr. Amit Oza. The expert panel participants 
included Drs. Marc Buyse, Mark Brady, Al Covens, 
Corneel Coens, Prafull Ghatage, Jean Gregoire, Hal 
Hirte, Paul Hoskins, Helen Mackay, Jean Maroun, 
Dianne Miller, Marie Plante, Diane Provencher, 
Barry Rosen, Gavin Stuart, Katia Tonkin, Johanne 
Weberpals, and Stephen Welch. The findings pre-
sented here represent ideas generated during the 
workshop with respect to
• an evaluation of the relevance of pfs as a valid 
endpoint in ovarian cancer.
• a Canadian consensus on the relevance of pfs in 
ovarian cancer.
• an attempt to address how pfs translates into clini-
cal benefit in ovarian cancer.
2. BACKGROUND
Ovarian cancer is the leading cause of gynecologic 
cancer mortality in Canada, responsible for an esti-
mated 2600 new cases and 1750 deaths in 2010 1. 
ABSTRACT
Ovarian cancer is leading cause of gynecologic can-
cer mortality in Canada. To date, overall survival (os) 
has been the most-used endpoint in oncology trials 
because of its relevance and objectivity. However, as 
a result of various factors, including the pattern of 
sequential salvage therapies, measurement of os and 
collection of os data are becoming particularly chal-
lenging. Phase ii and iii trials have therefore adopted 
progression-free survival (pfs) as a more convenient 
surrogate endpoint; however, the clinical significance 
of pfs remains unclear. This position paper presents 
discussion topics and findings from a pan-Canadian 
meeting of experts that set out to
• evaluate the relevance of pfs as a valid endpoint 
in ovarian cancer;
• reach a Canadian consensus on the relevance of 
pfs in ovarian cancer; and
• try to address how pfs translates into clinical 
benefit in ovarian cancer.
Overall, the findings and the group consensus 
posit that future studies should
• ensure that trials are designed to evaluate pfs, 
os, and other clinically relevant endpoints such 
as disease-related symptoms or quality of life;
• incorporate interim futility analyses intended to 
stop accrual early when the experimental regimen 
is not active;
• stop trials early to declare superiority only when 
compelling evidence suggests that a new treatment 
provides benefit for a pre-specified, clinically rel-
evant endpoint such as os or symptom relief; and
• discourage early release of secondary endpoint 
results when such a release might increase the 
CANADIAN POSITION PAPER ON PFS IN OVARIAN CANCER
S21Current OnCOlOgy—VOlume 18, Supplement 2Copyright © 2011 Multimed Inc. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC).
Most ovarian cancers are epithelial tumours, and the 
present review focuses on treatment and outcomes for 
the group of patients with that tumour type.
Currently, standard first-line treatment of advanced 
disease involves cytoreductive surgery combined with 
platinum-based chemotherapy 2. Most patients will 
initially respond well to treatment, but unfortunately, 
approximately three quarters of all women treated will 
develop recurrent disease and will no longer be consid-
ered curable 3. Treatment after recurrence focuses on 
prolonging life and improving quality of life (qol) 4. 
To that end, phase iii clinical trials are designed to as-
certain whether new treatments are superior to standard 
therapy or whether they positively affect patient qol 
(or both); to understand toxicity profiles; and to evalu-
ate the economic consequences of implementing the 
new treatments. Importantly, study endpoints must be 
clearly defined at the outset—the “ultimate endpoint” 
being to afford significant clinical benefit to the patient. 
To date, overall survival (os) has been considered the 
most clinically relevant endpoint in oncology trials; it 
remains the “gold standard” because of its relevance 
and objectivity.
3. OVARIAN CANCER AS A CHRONIC 
DISEASE AND THE CHALLENGES OF 
USING OS
It is widely recognized that os has become a chal-
lenging endpoint in oncology trials because of the 
prolonged time required to adequately assess sur-
vival and the delay in designing subsequent trials. 
Ultimately, this strategy is very costly. In addition, 
when os is used, confounding effects of post-study 
therapies and trial crossover (whereby patients who 
fail on standard-arm therapy are subsequently permit-
ted to switch to the experimental treatment) are seen.
The pattern of increasing sequential salvage 
therapies in ovarian cancer makes the measurement of 
os—and the individual effect of a specific therapy on 
that endpoint—more challenging. Because of biologic 
complexity in ovarian cancer, collection of os data is 
particularly challenging. Since about the end of the 
1950s, the median survival of women with advanced 
ovarian cancer has improved from less than 1 year to 
more than 3 years in most recent publications 5–7. Al-
though this progress may be related in part to patient 
selection, it has transformed ovarian cancer from an 
acute condition with limited treatment options into 
a chronic disease in which numerous treatments are 
used in sequence. As a result, to show a difference 
in os, contemporary trials must follow large cohorts 
of patients for prolonged periods.
In most trials, a significant consideration is that 
the analysis might be confounded by therapy received 
after progression. Data concerning os are especially 
likely to be obscured when trials are designed with a 
planned crossover to the experimental arm or when 
the likelihood is high that patients will subsequently 
receive the experimental treatment once they progress 
to the standard. Paradoxically, for ethical reasons and 
because of pressure from patients and physicians, 
crossover designs are more often used in the study 
of drugs presumed to be effective, thereby increasing 
the risk that any os benefit present in those newly 
developed effective treatments will be overshadowed.
Taken together, the foregoing factors have made a 
statistical proof of survival advantage derived from a 
single line of therapy difficult to attain even for active 
treatments. That difficulty has led to the adoption of 
more convenient—and in some cases, arguably more 
relevant—surrogate endpoints expected to correlate 
clinically and statistically with the original endpoint.
4. PFS AS A SURROGATE ENDPOINT
The most commonly used surrogate endpoint in on-
cology is pfs. The advantages of this endpoint are an 
earlier and more sensitive assessment of antitumour 
efficacy, a lower likelihood of influence by competing 
risks (especially in elderly subjects), and a lesser chance 
of confounding because of treatments received after 
progression. However, the clinical significance of pfs 
remains unclear. For pfs to be universally accepted as 
a surrogate for improved survival, delayed progression 
must be shown to correlate with improved survival, or 
alternatively, prolonged asymptomatic periods must be 
shown to translate into an improvement in qol. Con-
versely, absence of a pfs benefit must also be demon-
strated to mean that the experimental therapy is unlikely 
to yield a survival advantage. Those proofs should come 
in the form of statistical correlations between pfs and os 
data (where both are available) and of scores on vali-
dated qol tools incorporated into the study design. Also, 
in contrast to os, which relies on date of death (a bias-
free time point), pfs is based on predefined progression 
endpoints, which depend on bias-prone variables such as 
the methods of assessment, the moment of assessment, 
and the definition of progression. It can also be argued 
that statistical correlation between pfs and os is, in itself, 
not proof or indication of surrogacy 8 and that formal 
validation requires detailed observations and analysis. 
Yet, despite those limitations, pfs has been validated 
as correlating with os in some settings such as that of 
metastatic colorectal cancer 9,10.
We therefore convened the workshop reported 
here to discuss the existing evidence about the valid-
ity of pfs as a surrogate for os in the various clinical 
settings of ovarian cancer, with the aim of developing 
a consensus statement to guide those who ultimately 
determine drug approval policy.
5. PFS AND OS IN THE SETTING OF FIRST-
LINE TREATMENT OF OVARIAN CANCER—
THE EVIDENCE
A significant number of phase iii clinical trials as-
sessing first-line treatment for ovarian cancer have 
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been published. Many include data pertaining to pfs 
and os as primary or secondary trial endpoints, which 
allows for a direct comparison and assessment of the 
correlation between those outcomes. Our review of 
the literature revealed a significant number of trials 
illustrating correlated results for pfs and os, reflecting 
both positive and negative findings. Some of those 
results are summarized in the next subsection and in 
Table i.
In the setting of adjuvant treatment for women 
with early-stage ovarian cancer, the combined analy-
sis of icon1 (International Collaborative Ovarian 
Neoplasm 1) and action (Adjuvant Chemotherapy 
in Ovarian Neoplasm) observed a statistically sig-
nificant advantage in recurrence-free survival and 
os for patients receiving platinum-based adjuvant 
chemotherapy 12. In 1996, McGuire and colleagues 11 
established the superiority of the paclitaxel and cis-
platinum combination compared with the accepted 
standard combination of cyclophosphamide and 
cisplatinum. Their study showed a highly significant 
5-month pfs advantage and a 14-month survival ad-
vantage for the experimental combination 11. An Ar-
beitsgemeinschaft Gynäkologische Onkologie (ago)/
Groupe d’Investigateurs Nationaux pour l’Etude des 
Cancers Ovariens Intergroup study examined the use 
of triple combination therapy consisting of paclitaxel, 
carboplatin, and epirubicin compared with paclitaxel 
and carboplatin therapy. Based on analysis of pfs and 
os, no superiority for the triplet therapy was found. 
Because of its favored toxicity profile, the doublet 
therapy therefore remained the standard of care 13. 
In a separate phase iii study examining the utility of 
topotecan consolidation therapy after standard che-
motherapy, findings showed that pfs and os were not 
significantly affected by that addition, and the trial 
was concluded to be negative 14. Interestingly, a recent 
investigation by Katsumata et al., which compared the 
efficacy of a dose-dense combination of paclitaxel and 
carboplatin with the standard combination regimen, 
showed correlating evidence in the form of a pfs and 
an os favouring the dose-dense regimen 15.
Thus, there appears to be a correlation between 
pfs and os in the first-line setting for trials of cy-
totoxic chemotherapy, but it is unclear if the same 
holds true for trials incorporating targeted agents. 
The two first trials to report results for such agents 
were gog 218 (Gynecologic Oncology Group 218) and 
icon7. Those studies both examined the addition of 
bevacizumab, with or without a maintenance phase, 
to front-line chemotherapy. Preliminary results from 
both studies showed a clear pfs advantage favouring 
arms in which bevacizumab was administered both 
concurrently with chemotherapy and as maintenance 
therapy afterward 16. Survival data from those tri-
als are not yet mature, but interim analysis has so 
far failed to show a survival benefit. Those results 
highlight the importance of consensus with regard 
to the interpretation of data pertaining to pfs im-
provements and the acceptance of pfs as a surrogate 
endpoint when new classes of agents are introduced 
in randomized trials.
table i Selected trials in the first-line or adjuvant setting
Reference Patients p p
(trial name) (n) Arms pfsa Value osa Value
McGuire et al., 1996 11 410 Cyclophosphamide–cisplatin 13 months <0.001 24 months <0.001
Paclitaxel–cisplatin 18 months 38 months
Trimbos et al., 2003 12 925 Surgery alone 65% 0.001 74% 0.08
(icon1\action) Platinum-based adjuvant 76% 82%
(5-year rfs) (5-year os)
du Bois et al., 2004 13 1282 Paclitaxel–epirubicin–carboplatin 18.4 months ns 45.8 months ns
(ago-gineco) Paclitaxel–carboplatin 17.9 months 41.0 months
De Placido et al., 2004 14 273 Topotecan consolidation 18.2 months ns No values
No consolidation 28.4 months
Katsumata et al., 2009 15 637 Dose-dense paclitaxel–carboplatin 28 months 0.0015 72% 0.03
Standard paclitaxel–carboplatin 17.2 months 65%
(3-year os)
a   Median unless otherwise specified.
pfs = progression-free survival; os = overall survival; icon = International Collaborative Ovarian Neoplasm; action = Adjuvant Chemotherapy 
in Ovarian Neoplasm; rfs = relapse-free survival; ago = Arbeitsgemeinschaft Gynäkologische Onkologie; gineco = Groupe d’Investigateurs 
Nationaux pour l’Etude des Cancers Ovariens; ns = nonsignificant.
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Recently, a review article considered statistical 
approaches that may be of use in validating sur-
rogate endpoints. It concluded that meta-analysis 
based on individual patient data from multiple trials 
is an accurate method of validation. That approach 
was used to assess the validity of pfs as an accurate 
surrogate endpoint for os in ovarian cancer. The 
meta-analysis assessed four trials that all addressed 
the same treatment-related question in advanced ovar-
ian cancer patients and concluded that an acceptably 
high statistical correlation between pfs and os had 
been observed 17. However, all existing data reflect 
the use of cytotoxic treatments rather than targeted 
agents. Based on their differing mechanisms of action 
and their prolonged use, a conclusion cannot be made 
that the validity of pfs as an endpoint for cytotoxic 
therapy can be presumed for targeted therapies in the 
same clinical setting.
5.1 pfs in platinum-sensitive Relapse
The data presented so far demonstrate significant 
correlation between pfs and os in chemotherapy-
naïve patients. However, such a relationship is not 
yet well-defined in relapsed disease. Moreover, 
an important distinction should be made between 
platinum-sensitive and platinum-resistant patients.
It has been consistently demonstrated that ovar-
ian cancer sensitive to platinum agents (>6-month 
platinum-free interval) shows higher response rates to 
chemotherapy (including platinum agents) 18,19. That 
observation is important, because it translates into a 
longer time to disease progression, a higher survival 
rate, and longer treatment-free intervals 19. Thus, 
because of a lower rate of mortality events, trials of 
platinum-sensitive relapsed ovarian cancer (com-
pared with trials of platinum-resistant disease) have 
to accrue more patients and require longer follow-up 
to obtain meaningful survival data. Moreover, cor-
relating a qol benefit with pfs in platinum-sensitive 
disease can be challenging, because the incremental 
benefit in qol is likely to occur during treatment-free 
intervals, and experience has shown high, often non-
random, dropout rates for qol questionnaires in the 
latter phases of randomized clinical trials 20–22. This 
latter issue is not as likely to be a concern in studies 
of platinum-refractory disease, in which the time on 
treatment is shorter and the treatment-free interval is 
generally short-lived or nonexistent.
In contrast to the first-line setting, platinum-
sensitive recurrent ovarian cancer has few studies 
that assist in developing an assertion about whether 
pfs correlates with qol or os. The largest of the avail-
able trials—and the only one sufficiently powered 
to assess os—is the pooled analysis of two similarly 
designed phase iii trials: icon4 and avog (Associated 
Valley Obstetrics and Gynecology) 2.2. Those trials 
enrolled patients either to conventional platinum-
based chemotherapy or to platinum plus paclitaxel. 
The final analysis showed an advantage in pfs (13 
months vs. 10 months, p = 0.0004) that translated 
into an os advantage (29 months vs. 24 months, p = 
0.02) 23. Another smaller trial comparing single-agent 
paclitaxel with cyclophosphamide, doxorubicin, and 
cisplatin combination chemotherapy also showed a 
concordant benefit in pfs and os, with advantage to 
the platinum-based arm 24.
Many phase iii trials that are well designed to 
demonstrate a pfs advantage are not powered or con-
ducted to report a survival outcome. For example, the 
ago-led gcig (Gynecologic Cancer Intergroup) study 
in platinum-sensitive women (>6 months) compared 
single-agent carboplatin with a carboplatin–gem-
citabine combination and showed an advantage for 
pfs, but not for os, favouring gemcitabine 25. The 
second gcig study, led by the Grupo Español de In-
vestigación de Cáncer de Ovario, compared single-
agent carboplatin with a carboplatin and pegylated 
doxorubicin combination. The study was powered for 
pfs equivalence, but demonstrated that the median pfs 
was significantly superior for combination therapy. 
The os difference was not statistically different, how-
ever 26. It is important to emphasize that both trials 
were underpowered to assess os and that survival data 
may have been confounded by contamination of the 
control arm through use of the experimental drug in 
the community. Table ii summarizes selected trials.
For studies in which qol information was col-
lected, improvement in pfs did not translate into better 
qol. It should be noted that the quality of the data 
at later time points was limited 25–27, and as pointed 
out previously, was perhaps affected by nonrandom 
dropout, possibly obscuring qol benefits.
To summarize, current data concerning whether 
pfs correlates with os or qol in the setting of 
platinum-sensitive recurrent ovarian cancer are 
inconclusive. We emphasize, however, that os dif-
ferences can be challenging to demonstrate in this 
patient population because of previously described 
limitations such as a low event rate and contamina-
tion of the control arm. We also argue that extended 
time off therapy can, in itself, be a clinically relevant 
endpoint, although it has been difficult to prove by 
standardized qol questionnaires.
5.2 platinum-Resistant disease
Unfortunately, median survival is poor in platinum-
resistant ovarian cancer 28–30, and as a result, os data 
are easier to obtain and less likely to be confounded 
by post-trial therapy. In this setting, patients rarely en-
joy prolonged treatment-free intervals and frequently 
move from one treatment to another upon progression. 
However, data generated to date are insufficient to es-
tablish a definitive relationship between pfs and os or 
qol in patients with platinum-resistant disease. Only 
one randomized trial, which compared either topote-
can or pegylated doxorubicin with the experimental 
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drug canfosfamide, demonstrated a survival benefit 
(for the control arm) 28. However, in a retrospective 
analysis of eleven completed gog phase ii trials in 
platinum-refractory patients, pfs at 6 months in each 
trial correlated with os (Pearson r = 0.661, p = 0.027, 
and Kendall tau-b r = 0.514, p = 0.029) 29. That ob-
servation is particularly intriguing, but the absence 
of randomization and the retrospective nature of the 
analysis make its interpretation difficult.
Hence, our opinion is that an improvement in 
os or a clearly demonstrated improvement in qol 
scored using standardized qol questionnaires are the 
preferred endpoints in platinum-refractory ovarian 
cancer. That opinion holds particularly true if a trial 
is not likely to be hampered by contamination or 
crossover. Contamination or crossover are likely to 
occur in some trials, and in such cases, pfs remains 
a relevant endpoint that will need to be interpreted 
within the global context of the trial, taking into 
account frequency of crossover or contamination, 
magnitude of benefit, toxicity, qol, and costs associ-
ated with therapy.
As has been discussed, considerable support is 
available for the correlation between pfs and os in 
the first-line treatment of ovarian cancer. However, 
the relationship between pfs and os remains unclear 
in the context of relapsed disease and in the setting 
of maintenance therapy. The limitations of os as an 
endpoint should be recognized, and yet we believe 
that it may be appropriate to use pfs as the primary 
endpoint when
• crossover or contamination is expected.
• the absolute gain in pfs is clinically relevant.
•	 pfs is supported by one or more other endpoints 
(for example, os, qol).
It is important to note that the use of pfs as an end-
point must be validated before it will be accepted by 
regulatory authorities. Because the pfs-to-os correlation 
is not clear in most situations, it is essential to ensure 
that current studies are adequately powered for both 
os and pfs so that data supporting a strong correlation 
between these two endpoints can be accumulated.
There are pitfalls in the use of pfs as a surrogate 
for os. Surrogacy of pfs is highly tumour-dependent, 
and it may also be treatment-dependent, meaning that 
surrogacy may have to be re-established for every 
new class of treatment. Because individual trials may 
allow crossover or may have similar issues that may 
impair the establishment of a pfs-to-os correlation, 
evidence must come from meta-analyses of completed 
trials, including completed trials that did not address 
contemporary questions and that used older therapies 
and various definitions of pfs.
6. PFS IN THE SETTING OF MAINTENANCE 
THERAPY
The relationship between pfs and os for patients un-
dergoing maintenance therapy may be different from 
that for patients undergoing first-line therapy.
First, the current definition of maintenance che-
motherapy leaves several issues unresolved:
• Does “maintenance therapy” refer solely to 
patients in complete remission after induction 
treatment, or does it include those with residual 
disease?
• What do we call patients receiving “maintenance” 
after second- or third-line treatment?
• How are trials that treat until progression to be 
interpreted compared with those that continue 
table ii Selected trials in platinum-sensitive relapse
Reference Patients p p
(trial name) (n) Arms pfsa Value osa Value
Parmar et al., 2003 23 802 Conventional platinum-based 10 months 0.0004 24 months 0.04
(icon4/ago-ovar-2.2) Paclitaxel plus platinum 13 months 29 months
Cantù et al., 2002 24 97 Cyclophosphamide–doxorubicin–cisplatin 15.7 months 0.038 34.7 months 0.043
Single-agent paclitaxel 9 months 25.8 months
Pfisterer et al., 2006 25 356 Carboplatin 5.8 months 0.031 17.3 months ns
Carboplatin plus gemcitabine 8.6 months 18.0 months
Markman et al., 2010 26 61 Carboplatin 12 months 0.02 31 months 0.2
Carboplatin–pegylated doxorubicin 8 months 18 months
a   Median unless otherwise specified.
pfs = progression-free survival; os = overall survival; icon = International Collaborative Ovarian Neoplasm; ago = Arbeitsgemeinschaft 
Gynäkologische Onkologie; ns = nonsignificant.
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“maintenance therapy” for a predetermined period, 
and is the relationship the same for both scenarios?
The answers to those questions are currently 
unknown. Moreover, because each subsequent pro-
gression-free period may be shorter than the earlier 
ones, comparisons between trials may be difficult 
unless the patient populations are clearly defined.
The 2006 Workshop on Endpoints for Regulatory 
Approval (a joint effort of the U.S. Food and Drug 
Administration, the American Society of Clinical 
Oncology, and the American Association for Cancer 
Research) concluded that os is the most significant 
endpoint for studies involving maintenance che-
motherapy, but that improvement in pfs might be 
acceptable if the agent under investigation had few 
toxicities, if the potential for assessment bias were to 
be reduced (blinded designs were encouraged), and if 
biologic agents were not going to affect subsequent 
cytotoxic treatment 30. A Cochrane review of 902 
women in six trials of maintenance therapy failed to 
show a pfs or os benefit; however, the authors believed 
that they could not comment on the clinical benefit 
because of insufficient data 31. In a meta-analysis by 
Hess 3 in which the results of twenty consolidation 
and nine maintenance therapy trials were pooled, 
consolidation therapies were associated with im-
proved pfs [hazard ratio (hr): 0.79; p = 0.003] and 
os (hr: 0.68; p = 0.0008), and maintenance therapies 
were associated with improved pfs (hr: 0.82; p = 
0.02) and os (hr: 0.68; p = 0.007). This relationship 
remained statistically significant when sensitivity 
analyses were completed. Of the maintenance studies 
to date, issues arise from statistical design, crossover, 
lack of qol data, and censoring. As a result, the is-
sue of maintenance therapy and the use of pfs as a 
surrogate is impossible to answer at this time. In 
the trials to date, it remains unclear whether “early” 
second-line therapy benefit or true benefit are occur-
ring. Questions then arise about whether “time to 
third-line” therapy might be more relevant or whether 
maintenance strategies might be more effective after 
second- or third-line treatment than in the front line. 
Once again, the relationship might not be the same for 
cytotoxic agents (for example, paclitaxel) as it is for 
the biologic agents. Following on from the presenta-
tion of data from icon7 and gog 218, the mature os, 
qol, and health economic analyses from those studies 
are eagerly awaited.
7. PFS STANDARDIZATION AND THE ROLE OF 
CANCER ANTIGEN 125
The group acknowledged that the lack of standardized 
assessment of progression across ovarian cancer trials 
is problematic. The criteria used to define progression, 
the time points defined for the assessment of progres-
sion, and the methods of assessment can all affect the 
measured pfs. Although these issues are less likely to 
be problematic in randomized trials in which there 
is a comparator arm, they continue to hamper the 
comparison of pfs data from various single-arm trials.
One of the confounding factors in an evaluation of 
the use of pfs as an endpoint in clinical trials in ovar-
ian cancer is the role of cancer antigen 125 (CA125) 
in identifying progression. Many recent protocols 
are assigning a “progressive disease” date based on 
which of CA125 or objective progressive disease 
occurs first. However, how that approach may affect 
the pfs-to-os relationship is unknown. Although not 
consistently recognized by regulatory authorities, an 
increase in CA125 is well recognized by clinicians 
as an indicator of progression. However, an increase 
in CA125 is not always adequately confirmed 32, 
suggesting that identification of progression in clini-
cal trials could be inaccurate. Rustin et al. 32 showed 
that starting treatment based on increase in CA125 
does not improve survival, and CA125 levels may 
therefore not be a useful indicator for a determina-
tion of completion of treatment. Given that CA125 
has not been validated as an indicator of progression 
with new treatments, it is possible that the correlation 
between CA125 and tumour progression might not be 
robust for every class of agents, warranting prudence 
in clinical trials.
In past years, some clinical trials have incorporat-
ed the gcig criteria of CA125 progression, and some 
have relied solely on tumour measurement criteria 
such as the Response Evaluation Criteria in Solid 
Tumors. The results have been great heterogeneity in 
clinical trial results and confusion in interpretation. 
The use of CA125 in clinical trials of ovarian cancer 
warrants careful scrutiny and discussion so as to bet-
ter assess this parameter’s validity and to attempt to 
standardize its use.
8. SUMMARY
Progression-free and overall survival are important 
for understanding the full impact of any new treat-
ment, and thus either one may be designated as the 
primary endpoint for clinical trials in ovarian cancer. 
Although os is an important endpoint, pfs is usually 
preferred as the primary endpoint for clinical trials 
because of the confounding effect on os of post-
progression therapy. Despite the promising results of 
meta-analyses, the issue of whether pfs can be used as 
a surrogate for os is not yet resolved. An improvement 
in pfs is generally accepted as a good outcome, but 
treatment toxicities and qol must also be considered. 
These latter considerations hold particularly true for 
cytotoxic therapies in which the toxicities are more se-
vere, making smaller gains in pfs or os less attractive.
Not only must pfs be validated as an endpoint 
for metastatic ovarian cancer, but it must also be 
accepted by regulatory authorities as valid when ap-
proving new treatments. The ability to validate pfs as 
a surrogate for os is currently limited because clinical 
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trials are using older regimens as comparators, differ-
ent definitions of progressive disease, and conflicting 
statistical interpretations. There is a growing need for 
standardization of methods to assess progression so 
that biases are limited and separate clinical trials are 
made comparable and thus eventually amenable to 
pooling of data.
The pfs-to-os relationships may be different for 
different patient groups (such as platinum-refractory 
compared with platinum-sensitive, or first-line com-
pared with third line), possibly leading to contami-
nation of results when all patient types are pooled. 
Future research should attempt to determine if the 
pfs-to-os relationship varies with the patient group 
and should ensure that the full range of patient de-
mographics are made available so that data from the 
various patient groups can be pooled and analyzed 
separately. The most appropriate statistical analysis 
for evaluating clinical trials, particularly when pfs is 
being used as the primary endpoint, should also be de-
termined. Analyses such as restricted-means analysis, 
which analyzes all data and the areas under the curve 
for the standard and the experimental arm alike, may 
provide better sensitivity than is achieved by assess-
ing just the maximal differences between arms and 
should be explored to determine if more appropriate 
methods of assessing benefit can be developed.
Recommendations for future investigations in-
clude these:
• Ensure that trials are designed to evaluate pfs, 
os, and other clinically relevant endpoints such 
as disease-related symptoms or qol.
• Incorporate interim futility analyses intended to 
stop accrual early when the experimental regimen 
is not active.
• Stop trials early to declare superiority only when 
compelling evidence suggests that a new treat-
ment provides benefit for a pre-specified clinically 
relevant endpoint such as os or symptom relief.
• Importantly, discourage early release of second-
ary endpoint results when such a release might 
increase the frequency of crossover to the experi-
mental intervention.
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